RoboInd market brief: Robotic Biopsy Devices Market is estimated at USD 505.5 million in 2025. The report cites a CAGR of 15.8% over 2026–2033.
Market snapshot
- USD 505.5 million in 2025
- USD 600.3 million in 2026
- USD 1,675.4 million in 2033
Stated compound annual growth rate: 15.8% (2026–2033).
Market overview
The global robotic biopsy devices market size was valued at USD 505.5 million in 2025 and is projected to grow from USD 600.3 million in 2026 to USD 1,675.4 million by 2033, at a CAGR of 15.8% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 55.0% in 2025. This market growth is attributed to advancements in technology, such as improved precision and stability of robotic manipulators, enabling more accurate and minimally invasive procedures compared to traditional manual techniques
Market drivers and constraints
- Public report growth driver 1: The rising prevalence of cancer, along with an increasing emphasis on early detection, is driving the demand for robotic biopsy systems. Collaborations between research organizations and healthcare institutions are also providing growth opportunities for market players, further contributing to market expansion. The market is anticipated to grow as robotics and artificial intelligence, enhanced by the Internet of Things (IoT), become more prominent in the…
- Public report growth driver 2: In addition, the increasing incidence of lung cancer and other related diseases is leading to a higher adoption of biopsy devices in both developed and developing economies. The diverse applications of biopsy procedures drive growth in the biopsy devices market, and rising government initiatives for early cancer detection support their use.
- Public report growth driver 3: However, there is also a growing demand for minimally invasive procedures to reduce patient discomfort and speed up recovery. These medical instruments collect tissue samples from various parts of the body, enabling the diagnosis of conditions such as cancer, infections, and inflammatory diseases. Collecting tissue samples from the skin, lungs, liver, and kidneys offers significant benefits, including a lower risk of infection from less invasive techniques, which…
Applications and segments
- Instrument & Accessories
- Public report segmentation list
- Middle East and Africa (MEA)
Competitive landscape
Public report coverage names Johnson & Johnson MedTech, Zimmer Biomet Holdings, Inc, Integra LifeSciences Holdings Corporation. The list reflects participants identified by the source and is not a ranking.
Reading the figures: Values follow the market definition and forecast period stated in the source report. Estimates using different scopes should not be combined without normalization.